Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$1.00 USD
+0.04 (4.08%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $0.99 -0.01 (-0.92%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
MCRB 1.00 +0.04(4.08%)
Will MCRB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MCRB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MCRB
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now
MCRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Other News for MCRB
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Seres Therapeutics reports data from Cohort 2 of SER-155 Phase 1b study
Seres Therapeutics jumps on report of Nestle acquisition offer
Seres Therapeutics jumps on speculation of Nestle acquisition offer